Bio-Path Holdings to Present at the 2012 Southern California Investor Conference
<0> Bio-Path Holdings, Inc.Peter Nielsen, 832-971-6616President & Chief Executive OfficerorInstitutional Investors and AnalystsRx Communications Group, LLCRhonda Chiger, 917-322-2569orIndividual, Retail InvestorsPondel/Wilkinson Inc.Roger Pondel, 310-279-5980 </0>
Bio-Path Holdings, Inc., (OTCQX: BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that Peter Nielsen, President and Chief Executive Officer, will present a company overview at the 2012 Southern California Investor Conference in Newport Beach, Calif., on Thursday, August 30, 2012, at 3:00 p.m. Pacific Time.
A webcast ofMr. Nielsen’s remarks will be available live. You can access the webcast at the Company’s website: .
Bio-Path is a biotechnology company focused on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path’s lead product candidate, Liposomal Grb-2, is in a Phase I study for blood cancers. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. These product candidates and the delivery technology have been licensed from The University of Texas MD Anderson Cancer Center.
For more information, please visit the Company's website at .